Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxynitrone
- Development stage
- Unknown
- Lead developer
- GNI Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hydroxynitrone (also known by the code name F271) is a small molecule nitrone derivative developed by Shanghai Ruixing Gene Technology, a subsidiary of GNI Group. It is primarily being investigated for the treatment of liver fibrosis associated with chronic hepatitis B virus (HBV) infection. As a nitrone compound, it functions as a reactive oxygen species (ROS) scavenger, aimed at reducing oxidative stress-induced liver damage and subsequent fibrogenesis. The drug has undergone Phase I clinical evaluation in China, including pharmacokinetic and safety studies in healthy volunteers, to support its development as a potential therapy for chronic liver diseases.
- Other names
- 羟基硝酮
Beyond the preview
Go deeper on hydroxynitrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxynitrone.